



THE PEOPLE'S VACCINE

TABLE: SUMMARIZING MEASURABLE INDICATORS TOWARD A PEOPLE'S VACCINE

Company	Public Funding (est.) ¹	Price per course (est.)	COVID Vaccine Sales (est. 2021)	COVID Vaccine Profit (est. 2021)	Dose Distribution : High-Income Countries (est.)	Dose Distribution : Low- & Middle-Income Countries (est.)	CEO pay (FY2020)	Shareholder payouts (FY2020)
AstraZeneca / Oxford University (AZD1222)	\$2.7 billion	\$4.38 to \$10	\$1.9 billion	Undisclosed	1 billion doses (33%)	2 billion doses (67%)	\$21,089,782	\$3.6 bn in dividends (AstraZeneca)
Johnson & Johnson (Ad26COVS1)	\$1.5 billion	\$8.50 to \$10	Undisclosed	Undisclosed	901 million doses (43%)	1.2 billion doses (57%)	\$29,575,974	\$10.5 bn in dividends + \$3.2 bn in share buybacks = Total \$13.7 billion
Moderna / NIH (mRNA-1273 vaccine)	\$5.75 billion	\$24 to \$74	\$18.2 billion	\$5 billion	1.25 billion (97%)	35.2 million (3%)	\$12,855,275	Zero
Novavax (NVX-CoV2373)	\$2 billion	\$6-\$8.36	Undisclosed	Undisclosed	914 million (59%)	645 million (41%)	\$2,400,000 (FY2019)	Zero
Pfizer / BioNTech (BNT-162)	\$2.5 billion	\$13.50 to \$39	\$7.5 billion (Pfizer) \$7.5 billion (BioNTech)	\$2 billion (Pfizer) \$2 billion (BioNTech)	1.67 billion (85%)	290 million (15%)	\$21,033,570 (Pfizer)	\$8.44 bn in dividends (Pfizer)

¹ Transparency in public funding is lacking across all the COVID-19 vaccine developers, making firm figures difficult. Oxfam has arrived at these estimates by analyzing the research and development, manufacturing and advanced purchase deals made between the companies and some governments, notably the US. While Oxfam attempted to include all sources of public funding across these 3 areas (research and development, manufacturing and procurement), we were not able to be comprehensive due to contract opacity. Note also that these sums do not include the public investments in years of early research, which preceded COVID but was essential to these vaccines succeeding. These amounts also do not include purely philanthropic contributions. As a result, these estimates are conservative, and likely much less than the total public investments.